Generation Bio Co. GBIO
Set alert
5.34 USD 0.00 0.00%
As of Feb 10, 9:30 AM ET
5.34 Day range 5.34
52-week range unavailable
- YTD
- -5.99%
- 1 year
- -23.71%
- Open
- 5.34
- Prev close
- 5.34
- Mkt cap
- 73.47M
- Vol
- 551.92K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.34
- High
- 5.34
- Forward P/E
- -0.99
- Beta
- 2.82
- Short ratio
- 8.96
- Inst. own
- 82.94%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 1.77
- 200-d avg
- 2.65
- 1y target
- 7.50
2Y chart
Events in this range
- Mar 6, 2024Earnings: —; estimate -0.41; surprise —%
- Apr 10, 2024Rating: Needham · Buy → Buy
- May 13, 2024Earnings: -1.12; estimate -0.36; surprise -211.11%
- May 13, 2024Earnings: —; estimate -0.36; surprise —%
- May 14, 2024Rating: Wedbush · Outperform → Outperform
- May 14, 2024Rating: Needham · Buy → Buy
- Aug 7, 2024Earnings: -0.31; estimate -0.27; surprise -14.81%
- Aug 7, 2024Earnings: —; estimate -0.27; surprise —%
- Aug 8, 2024Rating: Needham · Buy → Buy
- Aug 8, 2024Rating: Wedbush · Outperform → Outperform
- Oct 23, 2024Rating: Needham · Buy → Buy
- Nov 6, 2024Earnings: -0.23; estimate -0.28; surprise 17.86%
- Jul 22, 2025Split: 1 for 10
Signals (93)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Feb 6, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 6, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 5, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 29, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 22, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 21, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 6, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 9 months ago |
| SMA: Bullish | Dec 24, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 26, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 18, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 13, 2025 | 11 months ago |
| SMA: Bearish | Nov 6, 2025 | 11 months ago |
| RSI: Oversold | Nov 6, 2025 | 11 months ago |
| SMA: Bearish | Oct 24, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 20, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 2, 2025 | 1 year ago |
| SMA: Bullish | Sep 26, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 29, 2025 | 1 year ago |
| RSI: Overbought | Aug 18, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 13, 2025 | 1 year ago |
| RSI: Overbought | Aug 13, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 1, 2025 | 1 year ago |
| RSI: Overbought | Jul 16, 2025 | 1 year ago |
| SMA: Bullish | Jul 11, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 18, 2025 | 1 year ago |
| SMA: Bearish | Jun 17, 2025 | 1 year ago |
| SMA: Bullish | Jun 16, 2025 | 1 year ago |
| SMA: Bullish | Jun 6, 2025 | 1 year ago |
| SMA: Bearish | Jun 4, 2025 | 1 year ago |
| SMA: Bullish | Jun 3, 2025 | 1 year ago |
| MACD: Buy Signal | May 13, 2025 | 1 year ago |
| MACD: Sell Signal | May 9, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 11, 2025 | 1 year ago |
| RSI: Oversold | Apr 4, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 1, 2025 | 1 year ago |
| RSI: Oversold | Mar 28, 2025 | 1 year ago |
| RSI: Oversold | Mar 14, 2025 | 1 year ago |
| RSI: Oversold | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 28, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 27, 2025 | 1 year ago |
| RSI: Oversold | Feb 20, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 18, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 11, 2025 | 1 year ago |
| RSI: Oversold | Feb 10, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 5, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 3, 2025 | 1 year ago |
| RSI: Oversold | Jan 30, 2025 | 1 year ago |
| RSI: Oversold | Jan 14, 2025 | 1 year ago |
| RSI: Oversold | Jan 8, 2025 | 1 year ago |
| RSI: Oversold | Dec 9, 2024 | 1 year ago |
| RSI: Oversold | Dec 5, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 3, 2024 | 1 year ago |
| RSI: Oversold | Nov 15, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 12, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 6, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 4, 2024 | 1 year ago |
| MACD: Buy Signal | Oct 29, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 18, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 16, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 27, 2024 | 2 years ago |
| SMA: Bearish | Sep 24, 2024 | 2 years ago |
| SMA: Bullish | Sep 19, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 12, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 4, 2024 | 2 years ago |
| SMA: Bearish | Aug 27, 2024 | 2 years ago |
| SMA: Bullish | Aug 26, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 21, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 5, 2024 | 2 years ago |
| SMA: Bullish | Jul 23, 2024 | 2 years ago |
| SMA: Bearish | Jul 18, 2024 | 2 years ago |
| SMA: Bullish | Jul 16, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 11, 2024 | 2 years ago |
| SMA: Bearish | Jun 14, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 14, 2024 | 2 years ago |
| SMA: Bullish | Jun 13, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 13, 2024 | 2 years ago |
| MACD: Sell Signal | May 24, 2024 | 2 years ago |
| SMA: Bearish | May 23, 2024 | 2 years ago |
| SMA: Bullish | May 14, 2024 | 2 years ago |
| MACD: Buy Signal | May 14, 2024 | 2 years ago |
| MACD: Sell Signal | May 13, 2024 | 2 years ago |
| SMA: Bearish | May 7, 2024 | 2 years ago |
| SMA: Bullish | May 6, 2024 | 2 years ago |
| MACD: Buy Signal | May 6, 2024 | 2 years ago |
| SMA: Bearish | Apr 24, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 9, 2024 | 2 years ago |
| RSI: Overbought | Apr 8, 2024 | 2 years ago |
| RSI: Overbought | Mar 27, 2024 | 2 years ago |
Key statistics
- Market cap
- 73.47M
- Enterprise value
- -11.51M
- Trailing P/E
- 0.00
- Forward P/E
- -0.99
- PEG ratio
- 0.00
- Price / sales
- 3.95
- Price / book
- 0.70
- EPS (TTM)
- -2.19
- Beta
- 2.82
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 18.58M
- Revenue growth
- 252.00%
- Free cash flow
- -49.25M
- Total cash
- 184.77M
- Total debt
- 93.78M
- Return on equity
- -86.50%
- Shares outstanding
- 66.79M
- Short % of float
- 3.82%
- 50-day average
- 1.77
- 200-day average
- 2.65
Analyst view
Consensus: none
Price target (mean) 7.50 +40.4% upside
Now 5.34
- Target (low)
- 5.00
- Target (mean)
- 7.50
- Target (high)
- 10.00
Ratings (0m) 7 4 buy · 3 hold · 0 sell
- Strong buy1
- Buy3
- Hold3
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.22546.
Financials — quick view
GBIO Revenue — quarterly 1.59M
GBIO Net income — quarterly -5.52M
GBIO EPS — quarterly -0.82
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.28 | -0.23 | +0.05 | +17.86% |
| Aug 7, 2024 | Jun 1, 2024 | -0.27 | -0.31 | -0.04 | -14.81% |
| Aug 7, 2024 | Jun 1, 2024 | -0.27 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.36 | -1.12 | -0.76 | -211.11% |
| May 13, 2024 | Mar 1, 2024 | -0.36 | — | — | — |
| Mar 6, 2024 | Dec 1, 2023 | -0.41 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 23, 2024 | Needham | reit | Buy | Buy |
| Aug 8, 2024 | Wedbush | reit | Outperform | Outperform |
| Aug 8, 2024 | Needham | reit | Buy | Buy |
| May 14, 2024 | Needham | reit | Buy | Buy |
| May 14, 2024 | Wedbush | reit | Outperform | Outperform |
| Apr 10, 2024 | Needham | reit | Buy | Buy |
About Generation Bio Co.
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- generationbio.com
News
- Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide
- Generation Bio Co. (NASDAQ:GBIO) Receives Average Recommendation of “Hold” from Brokerages
- Brokerages Set Generation Bio Co. (NASDAQ:GBIO) PT at $9.25
- Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders
- GBIO Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Generation Bio Co. is Fair to Shareholders
- XOMA Royalty Enters into Agreement to Acquire Generation Bio
- Generation Bio Announces Third Quarter 2025 Financial Results
- Comparing Generation Bio (NASDAQ:GBIO) & Nuvation Bio (NYSE:NUVB)
- Generation Bio Announces CEO Transition
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
Your note
Sign in to keep a note on GBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| APPELHANS DANNIELLE | Director | Purchase | Dec 7, 2023 | 0 |
| HOWZE YALONDA | Officer | Conversion of Exercise of derivative security | Oct 14, 2024 | 14,186 |
| KERR DOUGLAS | Officer | Conversion of Exercise of derivative security | Jan 28, 2024 | 385,628 |
| MCDONOUGH CAMERON GEOFFREY | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 14, 2024 | 1,839,090 |
| NORKUNAS MATTHEW | Chief Financial Officer | Conversion of Exercise of derivative security | Oct 14, 2024 | 57,348 |
| PAONE ANTOINETTE D | Chief Operating Officer | Conversion of Exercise of derivative security | Oct 14, 2024 | 16,055 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Associates Inc | 14.00% | 9,351,590 | 10.29M | Sep 29, 2024 |
| Atlas Venture Life Science Advisors, LLC | 12.40% | 8,279,484 | 9.11M | Sep 29, 2024 |
| FMR, LLC | 7.97% | 5,320,266 | 5.85M | Sep 29, 2024 |
| Bellevue Group AG | 5.87% | 3,918,856 | 4.31M | Sep 29, 2024 |
| Blackrock Inc. | 5.11% | 3,415,998 | 3.76M | Sep 29, 2024 |
| Siren, L.L.C. | 4.47% | 2,982,733 | 3.28M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) New Horizons Fund | 8.00% | 5,341,800 | 5.88M | Sep 29, 2024 |
| Fidelity Growth Company Fund | 2.72% | 1,818,215 | 2.00M | Oct 30, 2024 |
| Price (T.Rowe) Health Sciences Fund | 2.63% | 1,759,966 | 1.94M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.33% | 1,557,423 | 1.71M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.87% | 1,249,357 | 1.37M | Oct 30, 2024 |
| Price (T.Rowe) New Horizons Trust | 1.55% | 1,035,708 | 1.14M | Sep 29, 2024 |